Search Results
May 21, 2026, 16:05 ET TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
May 19, 2026, 16:05 ET TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
ANDOVER, Mass., May 19, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
May 05, 2026, 16:05 ET TransMedics Reports First Quarter 2026 Financial Results
ANDOVER, Mass., May 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported
More news about: TransMedics Group, Inc.
Apr 29, 2026, 09:26 ET TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
ANDOVER, Mass., April 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Apr 29, 2026, 09:00 ET The Quiet Rule Change Tilting $10B Toward Medtech's Most Validated Platforms
in that conversation: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Senseonics (NASDAQ: SENS), TransMedics Group (NASDAQ: TMDX), WELL Health Technologies (TSX: WELL) (OTCQX: WHTCF), and 10x Genomics (NASDAQ: TXG).
More news about: Equity Insider
Apr 23, 2026, 07:00 ET TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting
ANDOVER, Mass., April 23, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, is today providing
More news about: TransMedics Group, Inc.
Apr 21, 2026, 16:05 ET TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026
ANDOVER, Mass., April 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced
More news about: TransMedics Group, Inc.
Feb 27, 2026, 07:00 ET TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results
ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today issued
More news about: TransMedics Group, Inc.
Feb 24, 2026, 16:05 ET TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results
ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported
More news about: TransMedics Group, Inc.
Feb 20, 2026, 16:05 ET TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Feb. 20, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Feb 17, 2026, 16:05 ET TransMedics to Present at Upcoming March Investor Conferences
ANDOVER, Mass., Feb. 17, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Feb 10, 2026, 16:05 ET TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
ANDOVER, Mass., Feb. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced
More news about: TransMedics Group, Inc.
Feb 09, 2026, 08:00 ET TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial
ANDOVER, Mass., Feb. 9, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Jan 12, 2026, 08:10 ET TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts
ANDOVER, Mass., Jan. 12, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a global leader in organ transplant technologies and services, today announced the signing of a long-term lease for its new global headquarters at
More news about: TransMedics Group, Inc.
Dec 30, 2025, 16:05 ET TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
ANDOVER, Mass., Dec. 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Dec 24, 2025, 16:05 ET TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Dec. 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Nov 18, 2025, 16:05 ET TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference
ANDOVER, Mass., Nov. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Oct 31, 2025, 16:05 ET TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Oct. 31, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Oct 29, 2025, 16:05 ET TransMedics Reports Third Quarter 2025 Financial Results
ANDOVER, Mass., Oct. 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported
More news about: TransMedics Group, Inc.
Oct 15, 2025, 16:05 ET TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025
ANDOVER, Mass., Oct. 15, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced
More news about: TransMedics Group, Inc.
Sep 22, 2025, 02:00 ET TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
Sept. 22, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Sep 22, 2025, 02:00 ET TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
Sept. 22, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Aug 25, 2025, 16:05 ET TransMedics to Present at Upcoming September Investor Conferences
Mass., Aug. 25, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Aug 04, 2025, 08:00 ET TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial
Mass., Aug. 4, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Aug 01, 2025, 16:05 ET TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mass., Aug. 1, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.